ET-02 — Safety, Research, Risks & Legal Status

Not medical advice. ET-02 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	RS-5441
Category	Research Chemical
Developer	Eirion Therapeutics Inc. (acquired from Renascience); CEO Jon Edelson, MD
Alternate identifier	RS-5441
Phase 1 primary result	~6-fold increase in non-vellus hair count vs placebo with 5% formulation at 5 weeks (n~24, 4-week treatment)
Route of administration	Topical (5% formulation in Phase 1; oral formulation in preclinical development)
Mechanism distinction	Non-hormonal; does not inhibit androgen signaling - targets hair follicle stem cell reactivation
Current development stage	Phase 1 completed (2024-2025); Phase 2 (~150 subjects, 6 months) planned for 2025 initiation
US legal status	Investigational drug (United States). ET-02 is not FDA-approved and has no approved therapeutic indication. It is an active clinical-stage compound under IND-regulated study by Eirion Therapeutics Inc. It is not legally available for consumer purchase or personal use; any supply outside of enrolled clinical trials would be unapproved and unregulated.

What is ET-02?

ET-02 (also identified as RS-5441) is a topical small-molecule investigational drug being developed by Eirion Therapeutics Inc. for androgenic alopecia (AGA, pattern hair loss). It is designed to reactivate dormant hair follicle stem cells through a non-hormonal mechanism, distinguishing it from existing approved treatments such as finasteride (a 5-alpha reductase inhibitor) and minoxidil (a vasodilatory agent). The compound was originally developed by Renascience before being acquired by Eirion. Its specific chemical structure, binding targets, and detailed signaling pathway remain proprietary and have not been disclosed in open literature as of mid-2025.

How it works

ET-02 is described by its developer as a hair follicle stem cell reactivator. The proposed mechanism involves restoring normal biological function to dormant or senescent hair follicle stem cells, which are thought to underlie the progressive miniaturization and loss of terminal hairs in androgenic alopecia. Critically, the mechanism is stated to be non-androgenic - it does not inhibit androgen receptor signaling or 5-alpha reductase activity, and is therefore not expected to produce the endocrine-related adverse effects associated with finasteride (e.g., sexual dysfunction, mood changes). The molecular target and specific pathway have not been publicly disclosed. Broader supporting literature on follicle stem cell biology and metabolic reprogramming in aging follicles provides mechanistic plausibility, but ET-02's precise pharmacodynamic profile remains proprietary.

Background & history

ET-02 originated at Renascience and was subsequently acquired by Eirion Therapeutics Inc., a company founded and led by Jon Edelson, MD. Eirion initiated a first-in-human Phase 1 clinical trial, which was conducted across three US sites under double-blind, placebo-controlled conditions. Phase 1 results were presented in a late-breaking abstract (LB1158) at a major dermatology meeting and published in the Journal of Investigative Dermatology in 2025. Eirion announced plans for a Phase 2 trial in 2025, positioning ET-02 as a potential novel class of AGA therapy.

What the research says

Human clinical evidence for ET-02 is limited to a single completed Phase 1 trial (approximately 24 male subjects, 3 US sites, 4-week treatment, double-blind placebo-controlled, dose-ranging). The trial compared a 1.25% formulation, a 5% formulation, and a vehicle control. The primary reported outcome at 5 weeks was a roughly 6-fold increase in non-vellus hair count with the 5% formulation versus placebo. An approximately 10% improvement in non-vellus hair width versus placebo was also reported. The developer characterized the 4-week hair growth rate with ET-02 5% as comparable to approximately 4 months of minoxidil treatment, though this is a cross-trial comparison without a controlled head-to-head design and should be interpreted cautiously. The compound was reported as safe and well-tolerated in Phase 1 with no serious adverse events disclosed. A Phase 2 trial of approximately 150 subjects over 6 months was planned for 2025 initiation; it is expected to include female participants and will provide more robust safety and efficacy data. No Phase 2b or Phase 3 data exist. No long-term safety data exist. Preclinical work supporting the stem cell mechanism and a separate preclinical program exploring ET-02 for hair greying (targeting melanocyte stem cells) have been mentioned by the developer but not published in detail. An oral formulation is reportedly in preclinical development. All efficacy and safety conclusions remain preliminary pending larger controlled trials.

Reported effects

Non-vellus hair count increase vs placebo observed in Phase 1 (5% formulation, small n, short duration)
Non-vellus hair width improvement vs placebo reported in Phase 1 (~10%, same caveats apply)
Proposed reactivation of dormant hair follicle stem cells based on developer-stated mechanism
No androgenic or endocrine activity claimed; designed to avoid finasteride-class side effects
Melanocyte stem cell targeting for hair greying: preclinical stage only, no human data
All efficacy signals are preliminary Phase 1 data - larger trials have not yet reported

Dosing & administration (informational)

Published Phase 1 trial literature describes formulations of 1.25% and 5% topical concentrations applied over a 4-week period. These parameters are reported for clinical research documentation purposes only. No dosing protocol, regimen, or recommendation is appropriate outside of an enrolled clinical trial under physician supervision. Consult a licensed clinician and refer to any posted ClinicalTrials.gov protocol for trial participation details.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Phase 1 (n~24, 4 weeks) reported no serious adverse events and was described as well-tolerated
Long-term safety profile is unknown; Phase 2 (6 months) will provide the first extended exposure data
Non-hormonal mechanism is intended to avoid sexual dysfunction and endocrine adverse effects associated with finasteride
Topical route of administration may limit systemic exposure, but systemic pharmacokinetics have not been published
No comparative safety data versus approved standard-of-care therapies in controlled large populations
This compound is not approved for human use outside of clinical trials; use outside trials carries unknown risks

Drug & supplement interactions

D
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
f
o
r
E
T
-
0
2
h
a
v
e
n
o
t
b
e
e
n
p
u
b
l
i
s
h
e
d
.
T
h
e
n
o
n
-
h
o
r
m
o
n
a
l
m
e
c
h
a
n
i
s
m
t
h
e
o
r
e
t
i
c
a
l
l
y
r
e
d
u
c
e
s
t
h
e
l
i
k
e
l
i
h
o
o
d
o
f
e
n
d
o
c
r
i
n
e
-
p
a
t
h
w
a
y
i
n
t
e
r
a
c
t
i
o
n
s
,
b
u
t
t
h
i
s
h
a
s
n
o
t
b
e
e
n
s
t
u
d
i
e
d
.
C
o
n
c
o
m
i
t
a
n
t
u
s
e
w
i
t
h
o
t
h
e
r
t
o
p
i
c
a
l
s
c
a
l
p
a
g
e
n
t
s
(
m
i
n
o
x
i
d
i
l
,
t
o
p
i
c
a
l
f
i
n
a
s
t
e
r
i
d
e
,
k
e
t
o
c
o
n
a
z
o
l
e
s
h
a
m
p
o
o
s
)
h
a
s
n
o
t
b
e
e
n
e
v
a
l
u
a
t
e
d
.
N
o
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
a
r
e
a
v
a
i
l
a
b
l
e
.

Who should avoid it

Use outside of a registered clinical trial - no approved supply exists
Purchasing from any commercial vendor claiming to sell ET-02 or RS-5441 - no legitimate source exists outside trials
Assuming Phase 1 results predict Phase 2/3 outcomes - single small trial, effect size not confirmed in larger populations
Direct comparison with minoxidil efficacy based on developer cross-trial claims - no head-to-head RCT data
Use in women pending Phase 2 data - Phase 1 enrolled males only

How it is commonly combined

No stacking data exist. ET-02 has not been studied in combination with any other hair loss intervention. The non-hormonal mechanism may be theoretically complementary to androgen-pathway agents, but this is speculative and has not been investigated in any published or registered study.

Legal & regulatory. Investigational drug (United States). ET-02 is not FDA-approved and has no approved therapeutic indication. It is an active clinical-stage compound under IND-regulated study by Eirion Therapeutics Inc. It is not legally available for consumer purchase or personal use; any supply outside of enrolled clinical trials would be unapproved and unregulated.

Quality & harm reduction

Safer, legal alternative we recommend

Botani-GLOW Up. For the same hair-growth goal, our topical botanical hair serum is a legal, over-the-counter option you can actually buy today.

See our recommended pick

Find ET-02 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What is ET-02 and who is developing it?

ET-02 (also called RS-5441) is a topical small-molecule investigational drug developed by Eirion Therapeutics Inc. for androgenic alopecia. It originated at Renascience and was acquired by Eirion, which is led by CEO Jon Edelson, MD. It is not approved and is currently in early clinical development.

How does ET-02 differ mechanistically from finasteride and minoxidil?

ET-02 is described by its developer as a hair follicle stem cell reactivator that works through a non-hormonal pathway, distinct from finasteride (which inhibits 5-alpha reductase to reduce DHT) and minoxidil (which promotes vasodilation and has poorly understood direct follicle effects). The specific molecular target of ET-02 has not been publicly disclosed.

What does the human evidence actually show?

A single Phase 1 trial (approximately 24 male subjects, 4-week treatment, double-blind placebo-controlled) reported approximately a 6-fold increase in non-vellus hair count and roughly 10% improvement in hair width with the 5% formulation versus placebo at 5 weeks. These are promising but very preliminary signals from a small, short-duration study. No Phase 2 or larger trial data exist yet.

Can I get a dosing recommendation or protocol for ET-02?

No. ET-02 is an unapproved investigational compound with no established safe dosing regimen outside of a clinical trial protocol. The Phase 1 literature describes 1.25% and 5% formulations used in a controlled research setting. If you are interested in access, consult a clinician and monitor ClinicalTrials.gov for Phase 2 enrollment openings.

Is ET-02 available to buy?

No legitimate commercial supply of ET-02 exists. The compound is under IND-regulated clinical investigation by Eirion Therapeutics. Any vendor claiming to sell ET-02 or RS-5441 is selling an unverified, unapproved, and potentially counterfeit or hazardous substance.

What are the known safety concerns?

Phase 1 reported no serious adverse events and the compound was described as well-tolerated, but this was a small (n~24) and short (4-week) study. Long-term safety is unknown. The non-hormonal mechanism is intended to avoid the endocrine-related adverse effects of finasteride, but this claim has not been validated in large populations. Phase 2 will provide the first extended exposure safety data.

References & further reading

PubMed: hair follicle stem cells androgenic alopecia small molecule reactivation
PubMed: ET-02 RS-5441 Eirion Therapeutics alopecia
Journal of Investigative Dermatology: LB1158 novel topical therapeutic androgenic alopecia 2025 abstract
ClinicalTrials.gov: ET-02 OR RS-5441 androgenic alopecia Phase 2 (expected posting 2025)
PubMed: follicle stem cell metabolic reprogramming aging hair loss